Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma

Summary

This phase II trial studies how well giving brentuximab vedotin together with combination chemotherapy works in treating older patients with previously untreated stage II-IV Hodgkin lymphoma (HL). Monoclonal antibody-drug conjugates, such as brentuximab vedotin, can block cancer growth in different ways by targeting certain cells. Drugs used in chemotherapy, such as doxorubicin hydrochloride, vinblastine, and dacarbazine (AVD), work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving brentuximab vedotin, doxorubicin hydrochloride, vinblastine, and dacarbazine together may kill more cancer cells.

Conditions

• Adult Lymphocyte Depletion Hodgkin Lymphoma
• Adult Lymphocyte Predominant Hodgkin Lymphoma
• Adult Mixed Cellularity Hodgkin Lymphoma
• Adult Nodular Sclerosis Hodgkin Lymphoma
• Stage II Adult Hodgkin Lymphoma
• Stage III Adult Hodgkin Lymphoma
• Stage IV Adult Hodgkin Lymphoma

Interventions

DRUG

brentuximab vedotin

Given IV

DRUG

doxorubicin hydrochloride

Given IV

DRUG

vinblastine

Given IV

DRUG

dacarbazine

Given IV

PROCEDURE

quality-of-life assessment

Ancillary studies

GENETIC

DNA analysis

Optional correlative studies

GENETIC

RNA analysis

Optional correlative studies

RADIATION

fludeoxyglucose F 18

Correlative studies

PROCEDURE

positron emission tomography

Correlative studies

OTHER

laboratory biomarker analysis

Optional correlative studies

OTHER

immunohistochemistry staining method

Optional correlative studies

GENETIC

polymorphism analysis

Optional correlative studies

Sponsors & Collaborators

• Robert H. Lurie Cancer Center

  collaborator OTHER

• Seagen Inc.

  collaborator INDUSTRY

• Northwestern University

  lead OTHER

Principal Investigators

• Leo Gordon, MD · Northwestern University

Study Design

Allocation

NA

Purpose

TREATMENT

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

60 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2011-11-30

Primary Completion

2017-04-06

Completion

2020-05-26

Countries

• United States

Study Locations